AVXL vs. TRML, AURA, SLDB, TNYA, MGTX, CRBU, BDTX, REPL, CCCC, and JSPR
Should you be buying Anavex Life Sciences stock or one of its competitors? The main competitors of Anavex Life Sciences include Tourmaline Bio (TRML), Aura Biosciences (AURA), Solid Biosciences (SLDB), Tenaya Therapeutics (TNYA), MeiraGTx (MGTX), Caribou Biosciences (CRBU), Black Diamond Therapeutics (BDTX), Replimune Group (REPL), C4 Therapeutics (CCCC), and Jasper Therapeutics (JSPR). These companies are all part of the "biological products, except diagnostic" industry.
Anavex Life Sciences (NASDAQ:AVXL) and Tourmaline Bio (NASDAQ:TRML) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, community ranking, institutional ownership, valuation, profitability, analyst recommendations, earnings, media sentiment and risk.
Anavex Life Sciences presently has a consensus target price of $40.00, suggesting a potential upside of 788.89%. Tourmaline Bio has a consensus target price of $61.80, suggesting a potential upside of 319.27%. Given Anavex Life Sciences' higher possible upside, equities research analysts plainly believe Anavex Life Sciences is more favorable than Tourmaline Bio.
In the previous week, Tourmaline Bio had 15 more articles in the media than Anavex Life Sciences. MarketBeat recorded 21 mentions for Tourmaline Bio and 6 mentions for Anavex Life Sciences. Tourmaline Bio's average media sentiment score of 0.51 beat Anavex Life Sciences' score of 0.29 indicating that Tourmaline Bio is being referred to more favorably in the news media.
31.6% of Anavex Life Sciences shares are held by institutional investors. Comparatively, 91.9% of Tourmaline Bio shares are held by institutional investors. 11.0% of Anavex Life Sciences shares are held by insiders. Comparatively, 11.0% of Tourmaline Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Anavex Life Sciences is trading at a lower price-to-earnings ratio than Tourmaline Bio, indicating that it is currently the more affordable of the two stocks.
Anavex Life Sciences has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500. Comparatively, Tourmaline Bio has a beta of 2.42, meaning that its share price is 142% more volatile than the S&P 500.
Anavex Life Sciences received 414 more outperform votes than Tourmaline Bio when rated by MarketBeat users. However, 100.00% of users gave Tourmaline Bio an outperform vote while only 74.13% of users gave Anavex Life Sciences an outperform vote.
Tourmaline Bio's return on equity of -19.56% beat Anavex Life Sciences' return on equity.
Summary
Tourmaline Bio beats Anavex Life Sciences on 11 of the 14 factors compared between the two stocks.
Get Anavex Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for AVXL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AVXL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Anavex Life Sciences Competitors List
Related Companies and Tools
